Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA

By Fernández-Torres Rosa María   Paradela Sabela   Fonseca Eduardo  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 54-56

Informa Healthcare

Access to resources Recommend Favorite

An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis

By Gupta Rishu   Levin Ethan   Wu Jashin J.   Koo John   Liao Wilson  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 87-89

Informa Healthcare

Access to resources Recommend Favorite

Exfoliative Dermatitis after Long-term Methotrexate Treatment of Severe Psoriasis

By Peters Thorsten   Theile-Ochel Susanne   Chemnitz Jens   Söhngen Dietmar   Hunzelmann Nicolas   Scharffetter-Kochanek Karin  

Acta Dermato-Venereologica, Vol. 79, Iss. 5, 1999-08 ,pp. : 391-392

Medical Journals Limited

Access to resources Recommend Favorite

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

By Lynde Charles  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite